Application of hyperbaric oxygenation in patients with a new coronavirus infection COVID-19: prospective study

OBJECTIVE: To study the effect of hyperbaric oxygenation HBO on the dependence of COVID-19 patients on constant oxygen support and clinical and biochemical parameters that are markers of the severity of this pathological condition.
MATERIAL AND METHODS: 30 patients were examined with the diagnosis of “Coronavirus infection caused by the SARS-CoV-2 virus” (20 - CT1-2 patients, 10 – CT 3-4 patients) who were on constant oxygen support from the first day of admission to the hospital. Twenty patients (the main group) were assigned a six-day course of hyperbaric oxygenation (HBO) in the mode of 1.4 ata - 60 min, one session per day. The procedure was carried out in the domestic pressure chamber “BLKSM”. At the time of the appointment of the HBO course, the patients were on endonasal oxygen supply for 3 to 5 days (EOS, 8-10 liters per minute) or from 2 to 4 days on noninvasive ventilation of the lungs (NIVL). The indication for the appointment of HBO was the inefficiency of the oxygen support provided. Before and after each HBO session, the patient’s subjective state was assessed, blood oxygen saturation was measured, the dynamics of the content of leukocytes, platelets, C-reactive protein (CRP), ferritin and transferase activity were evaluated. The control group (10 people) consisted of COVID-19 patients who had contraindications to the use of HBO (claustrophobia, bullous lung disease). Statistics. Statistical processing of the obtained data was carried out using the program “Statistica 10.0” (Dell Inc., USA).
RESULTS: Already by the 3rd HBO session, five out of 10 COVID-19 c CT1-2 patients did not need constant oxygen support, and 4 out of 5 COVID-19 c CT 3-4 patients switched from NIV to EOS. After the 6th HBO session, only one patient needed constant oxygen support (EOS), which was canceled 4 days after the end of the HBO course. There was no lethality in this group. In patients of the control group, oxygen support was distributed as follows: on the first day - 8 people on EOS, 2 on NIVL; on day 3- 4 people on EOS, 6 on NIVL; on day 7 -3 people on EOS, 4 on NIVL, two on invasive ventilation of the lungs (IVL). By the 14th day, five people did not need constant oxygen support, 2 on EOS. 1 on NIVL; two patients who were on a ventilator died. In the main group, the elimination of hypoxemia was noted on the 6th day of HBO use, whereas in the control group it persisted by the 14th day of treatment. Regardless of the severity of the pathological process, the use of HBO caused a decrease in the content of blood leukocytes, not exceeding the lower limit of the norm, reduced the degree of hyperferritinemia. The rate of decrease in the blood of C-reactive protein (CRP) under the influence of HBO was inversely dependent on the severity of the pathological condition.
DISCUSSION: The rapid refusal of patients with COVID-19 from constant oxygen support during the course of the use of HBO indicates the ability of hyperbaric oxygen to eliminate violations of the gas exchange function of the lungs. At the same time, HBO has an anti-inflammatory effect on the sick body, acting as a synergist with drug therapy, which is manifested by a decrease in the content of acute phase proteins in the blood and the elimination of leukocytosis. The rate of decrease in the blood of C-reactive protein (CRP) under the influence of HBO was inversely dependent on the severity of the pathological condition.
CONCLUSION: Course application of HBO in 1.4 ata mode, 50 min, one session per knock. It is an effective method of treating respiratory failure and preventing its progression in patients with COVID-19.

1. Guan W., Ni Z., Hu Yu., Liang W. Clinical characteristics of coron-avirus disease 2019 in China. N. Engl. J. Med, 2020, Vol. 382, № 18, pp. 1708–1720. doi: 10.1056/NEJMoa2002032.

2. Joly B.S., Siguret V., Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med, 2020, Vol. 46, № 8, рр. 1603–1606. doi: 10.1007/s00134-020-06088-1.

3. Glybochko P.V., Fomin V.V., Moiseev S.V. Outcomes in patients with severe COVID-19 hospitalized for respiratory support in intensive care units. Clinical pharmacology and therapy, 2020, No. 3, pp. 25–36 (In Russ.) doi: 10.32756/0869-5490-2020-3-25-36.

4. Henry B.M., Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports // J. Crit Care, 2020, Vol. 58, pp. 27–28. doi:10.1016/j.jcrc.2020.03.01

5. Savilov P.N. On the possibility of using hyperbaric oxygenation in the treatment of SARS-CoV-2 infected patients. Danish Scientific Journal, 2020, Vol. 1, № 36, pp. 43–49.

6. Howell R.S., Criscitelli T., Woods J.S., Gillette B.M., Gorenstein S. Hyperbaric oxygen therapy: indications, contraindications, and use at a tertiary care center. AORN J, 2018, Vol. 107, № 4, pp. 442–453. doi:10.1002/aorn.1209

7. Thibodeaux K., Speyrer Z., Raza A. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. Journal of Wound Care, 2020, Vol. 29, Suppl. 5a, pp. S4–S8. doi:%2010.12968/jowc.%202020.29.%20Sup5a.S4.

8. Paganini M., Perozzo B.G., F.A.G. The role of hyperbaric oxygen treatment for COVID-19: a review. Advances in Experimental Medicine and Biology, 2020, Vol. 1289, pp. 27–35. doi: 10.1007/5584_2020_568.

9. Levina O.A., Evseev A.K., Shabanov A.K. Safety of hyperbaric oxygenation in the treatment of COVID-19. N.V. Sklifosovsky Journal «Emergency medical care», 2020, Vol. 9, No. 3, pp. 14–19 (In Russ.) doi: 10.23934/2223-9022-2020-9-3-314-320.

10. Efremova O.Yu., Zaitsev A.A., Zolotukhin O.V., Kostina N.E. The experience of using hyperbaric oxygenation in oxygendependent patients with severe forms of coronavirus infection. Proceedings of the XXX National Congress on Respiratory Diseases with international participation / edited by A.G. Chuchalin. Moscow, 2020, p. 113 (In Russ.)

11. Grippi М.А. Pathophysiology of the lungs / translated from English by Yu.M. Shapkaits edited by Yu. V. Natochin. 2nd ed., ispr. Moscow; St. Petersburg: BINOM, Nevsky Dialect, 1999, 344 p. (In Russ.)

12. Petrikov S.S., Evseev A.K., Levina О.А., Shabanov А.К., Goroncharovskaya I.V., Potapova N.A., Slobodeniuk D.S., Grin А.А. The effectiveness of the inclusion of hyperbaric oxygenation in the complex therapy of patients with COVID-19: retrospective study. Marine medicine, 2022, Vol. 8, No. 3, pp. 48–61 (In Russ.) doi: 10.22328/2413-5747-2022-8-3-48-61

13. Grebennikova I. V., Lidokhova O. V., Makeeva A.V. Age-related aspects of changes in leukocyte indices in COVID-19. Scientific and Medical Bulletin of the Central Chernozem region, 2022, No. 87, pp. 9–15 (In Russ.)

14. Efremova O.Yu. Hyperbaric and normobaric oxygenotherapy in the pathology of pregnant women. II. Hyperbaric oxygenation in the complex treatment of fetoplacental insufficiency. Bulletin of hyperbaric biology and medicine, 2004, Vol. 12, No. 3–4, pp. 27–34 (In Russ.)

15. Savilov P. N. Hepatic blood flow and oxygen tension in different types of liver damage and hyperoxia. Patologucal and Experimental Therapy, 2020, Vol. 64, No. 2, pp. 54–62 (In Russ.) doi: 10 25557/0031-2991 2020 02 54-62.

16. Leonov A.N. Hyperoxia. Adaptation. Sanogenesis. Voronezh: VGMA Publishing House, 2006, 190 р. (In Russ.)

17. Savilov P.N. Effects of hyperoxic aftereffect and posthyperoxic state of the organism. Bulletin of hyperbaric biology and medicine, 2006, Vol. 14, No.1–4, pp. 21–51 (In Russ.) doi:10.24412-3453-9875-2021-65-1-29-40

18. Savilov P.N. Hyperoxic sanogenesis of lings Gas exchang function in SARS_CoV2-associated pneumonia. Norvegian Journal of development of the international Science, 2021, Vol. 65, № 1, pp. 29–40. doi:10.24412-3453-9875-2021-65-1-29-40

19. Savilov P.N. Forms of Adaptation to Hyperoxia. Norvegian Journal of development of the international Science, 2021, Vol. 1, № 55, pp. 26–32. doi:10.24412/3453-9875-2021-55-1-26-32

20. Naumov A.V., Artsimenya L.T., Bindich E.Yu., Naumova N.V. S-reactive protein. Journal of Grodno Medical University, 2010, No. 4, pp. 3–10. (In Belorus)

21. Kushner I., Jiang S.L., Zhang D., Lozanski G., Samols D. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1. Ann. N. Y. Acad. Sci, 1995, Vol. 762, pp. 102–107. doi: 10.1111/j.1749-6632.1995.tb32318.x

22. Orlov Yu.P., Ivanov A.V., Dolgikh V.T. Impaired Iron Metabolism in the Pathogenesis of Critical Conditions (an Experimental Study). General resuscitation, 2005, Vol. 1, № 5, рp. 5–12 (In Russ.)

23. Finazzi D., Arosio P. Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch Toxicol, 2014, Vol. 88, № 10, pp. 1787–802. doi:10.1007/s00204-014-1329-0